Supplementary Table 1. Exact p-values for figure 2.

URINE

Adjusted P-value	FE Ca	Oxalate	Uric Acid	Phosphate	Volume	Citrate	Sodium	Magnesium	TmP/GFR	рН	Osmolality	Free Water Clearance
FD15	0.003370	>0.999999	0.056845	0.002058	0.000821	0.810013	>0.999999	0.000048	0.024698	>0.999999	0.079428	0.004040
FD30	0.000140	>0.999999	>0.999999	0.057221	0.000509	0.066749	>0.999999	0.024692	0.000111	>0.999999	0.125996	0.013957
FD60	0.004693	0.754059	0.343394	0.010473	0.097799	0.426127	>0.999999	0.018395	0.006865	>0.999999	0.360883	0.021602
FD120	0.806656	0.342796	>0.999999	0.032661	0.559921	>0.999999	>0.999999	0.016368	0.000555	>0.999999	0.860033	0.213379
FD180	>0.999999	0.017162	0.026069	0.000329	0.514957	>0.999999	>0.999999	0.027750	0.001692	>0.999999	0.236701	0.037563
R+0	>0.999999	>0.999999	0.015445	0.000002	0.505191	>0.999999	0.000568	0.007798	0.000711	>0.999999	>0.999999	>0.999999
R+1		>0.999999								0.019312		
R+30	>0.999999	>0.999999	>0.999999	>0.999999	0.866086	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999	>0.999999
R+31		>0.999999								>0.999999		
ANOVA summary	<0.0001	0.001424	<0.000001	<0.000001	0.001594	0.014056	0.000034	<0.000001	0.000011	0.012060	0.008156	0.000023

BLOOD

Adjusted P- value	1,25-Dihydroxyvitamin D3	РТН	FGF-23	Renin	Aldosterone	Atrial Natriuretic Peptide
FD15	>0.999999	0.015767	>0.999999	0.011353	>0.999999	0.033014
FD30	0.013625	0.006488	>0.999999	0.002332	0.881279	0.003087
FD60	0.528434	0.133337	>0.999999	0.036261	>0.999999	0.003087
FD120	0.319539	0.822117	>0.999999	0.008913	>0.999999	0.000194
FD180	>0.999999	>0.999999	>0.999999	0.006545	>0.999999	0.015679
R+0	0.000028	>0.999999	0.198271	>0.999999	>0.999999	>0.999999
R+1	>0.999999					
R+30		<0.000001	>0.999999	>0.999999	>0.999999	>0.999999
ANOVA summa	ry <0.000001	<0.000001	0.075601	0.000181	0.207730	<0.000001

Supplementary Figure 1: Human plasma and urine physiological measurements

a, Urinary and **b**, plasma physiological measurements from NASA astronauts (n=66) exposed to spaceflight up to 180 days and **c**, plasma physiological measurements from Inspiration4 SpaceX astronauts exposed to spaceflight for 3 days. Values were measured pre-flight, during (FD = flight day) and after returning (R). Dashed lines represent upper and lower normal clinical values, or upper limit where only a single line is present. Data are presented as mean ± SD. Boxed P-values report the repeated measure one-way ANOVA result; all timepoints were compared to pre-flight by pairwise multiple comparison Bonferroni corrected post-hoc tests (* p < 0.05, ** p < 0.01, **** p < 0.001, **** p < 0.0001). FE; fraction excretion. TTKG; trans-tubular potassium gradient. Corrected; corrected for albumin. Na; sodium. K; potassium. Mg; magnesium. Cl; chloride. P₀₄; phosphate. H2O; water. eGFR; estimated glomerular filtration rate corrected for body surface area (BSA). 25-hydroxyvitamin D3; calcifediol. BUN; blood urea nitrogen.



20-

15

10-Ratio

5


0-

-5

015 40³⁰

x


Calcium:Creatinine




TTKG


40⁶⁰401²⁰401⁸⁰

۲ مرجع ' 4^x%





 $\mathsf{FE}_{\mathsf{Mg}}$








FE_{Mg} (Corr)





















Specific Gravity





b

















Chloride 110· 105 mmol/L P <0.0001 95 F0180 \$*0 4030 F0120 4×30 £060 4015 ð

Aldosterone:Renin

4×0 . ه^{* به}

President 4015 4030 4060 4012 40180


60-

40-


0

-20

Ratio 20





Cholesterol 240 220· 200 mg/dL 180 160 140 120 ₽^{*}° , ⁴⁰⁶⁰ FD180 \$039 401⁵




\$**


4×30






Magnesium 2.5 2.0 mg/dL P <0.0001 1.0 reflight ED15 ED30 ED80 ED120 ED180 4×0 4×30







С



Supplementary Figure 2: Multi-omic DisGeNET over-representation analysis top 100 results by category grouping

The top 100 enriched gene-disease associations are presented for DisGeNET ontological terms relating to **a**, kidney health [kidney; urological; electrolyte; mitochondrial (general); complement; urinary system cancers; blood pressure (renal)], b, closely related to kidney injury and disease [Vascular/endothelial; cardiovascular; autonomic dysfunction; diabetes; blood pressure (general)], c, general diseases known to impact the kidney [nonurinary systems cancers; aging; inflammation; liver], d, no clear connection to the kidney. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.g. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A Log10(P-value) of 2 was considered significant for ontological term enrichment. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.

а		
Omic	Expo	mple
Epiproteome Proteome	C0002726: Amyloidosis	••••••••••••
Transcriptome Metagenome	C0085580: Essential Hypertension - C2316810: Chronic kidney disease stage 5 -	
Metabolome Epigenome	C0151650: Renal fibrosis	••••• ••• ••••
Species	C1565489: Renal Insufficiency - C0027726: Nephrotic Syndrome -	
Mouse Human	C0017665: Membranous glomerulonephritis	••••
Rat	C0017661: IGA Glomerulonephritis - C0178664: Glomerulosclerosis (disorder) -	
Exposure Spaceflight	C0041956: Ureteral obstruction	••••
simGCRsim	C1378703: Renal carcinoma	
GCRsim MGsim	- C0740457: Malignant neoplasm of kidney - C0033687: Proteinuria	••••• ••••••••••••••••••••••••••••••••
Sample	C0740394: Hyperuricemia -	•••• ••••••
Kidney Plasma	C1969372: Tubulointerstitial fibrosis - C0268731: Renal glomerular disease -	
Exosome Faeces	C0085413: Polycystic Kidney, Autosomal Dominant	•• • ••••••
	C0392525: Nephrolithiasis C0027708: Nephroblastoma -	
	C0022650: Kidney Calculi	•••••••
LagP ● 2.5	C0011644: Scleroderma	••••••
• 5.0	C0001787: Osteoporosis, Age-Related - C0005940: Bone Diseases -	· · · · · · · · · · · · · · · ·
• 7.5 • 10.0	C0017668: Focal glomerulosclerosis	•••• • ••• •
12.515.0	C0035126: Reperfusion Injury - C1527336: Sjogren's Syndrome -	· ·· · ·· · ·· ·· ·· ··
	C0011175: Dehydration -	•••••
	C0262655: Recurrent urinary tract infection -	••••••••••
0.14	C0029459: Osteoporosis, Senile - C0022665: Kidney Neoplasm -	
	C0027720: Nephrosis	•• •• ••• •••
- 0.12	C1306837: Papillary Renal Cell Carcinoma - C0027709: Nephrocalcinosis -	• • • • • • • • • • • • • • • • • • •
	C0342649: Vascular calcification	••• •• ••••
- 0.10	C1333015: Childhood Kidney Wilms Tumor	• • • • • • • • • • •
. 0.08 ti	C0740447: Diabetic peripheral neuropathy C0151449: Primary Sjögren's syndrome	• • • • • • • • • • • • • • • • • • •
80.0 - Eurichmen 1000 -	C0041341: Tuberous Sclerosis	••••
- 0.06 E	C2145472: Urothelial Carcinoma C0022680: Polycystic Kidney Diseases	
	C0034152: Henoch-Schoenlein Purpura	•• ••• ••
- 0.04	C1266042: Chromophobe Renal Cell Carcinoma - C0024523: Malabsorption Syndrome -	•••• • • ••••
	C0027831: Neurofibromatosis 1	• • • • • • •
- 0.02	C0920646: Ischemia of kidney	••• •• •• •
	C2931852: Clear-cell metastatic renal cell carcinoma - C0042580: Vesico-Ureteral Reflux -	• • • • • • •
	C4721698: Metastatic Renal Cell Carcinoma	• • • • • • •
	C0278678: Metastatic Renal Cell Cancer - C0410158: Muscle damage -	• • • • • • • • • • •
	C0872084: Sarcopenia	•• • • • • • •
	C1827293: Carcinoma of urinary bladder, invasive - C1266044: Collecting Duct Carcinoma of the Kidney -	
	C0017654: Glomerular Filtration Rate	••••
	- C0020295: Hydronephrosis - C1704321: Nephrotic Syndrome, Minimal Change	
	C0019562: Von Hippel-Lindau Syndrome	• • • • • • •
	C0020428: Hyperaldosteronism - C0020545: Hypertension, Renovascular -	· · · · · · · ·
	C0848548: hypertension, kenovascular C0848548: hypertensive nephropathy -	•• •••
	C4020732: Mitochondrial abnormalities -	• • • • •
	C4021821: Abnormality of the urinary system C0162678: Neurofibromatoses	••••
	C0020598: Hypocalcemia	• • • • • •
	C0027832: Neurofibromatosis 2 - C0020437: Hypercalcemia -	• • • • •
	C0151723: Hypomagnesemia	• • • • •
	C0032617: Polyuria -	
	C0020488: Hypernatremia - C0020438: Hypercalciuria -	• •• ••
	C0013604: Edema	• • • • •
	C2718001: Protein Misfolding Disorders - C4721411: Osteolysis -	• • • • •
	C1963165: Malabsorption, CTCAE	• • • •
	C3714745: Malabsorption - C0020503: Hyperparathyroidism, Secondary -	• • • • •
	C0266295: Congenital hypoplasia of kidney -	• • • •
	C3887499: Renal cyst C0022679: Cystic kidney -	••• •
	C1567741: Alport Syndrome -	•• •• •
	C4288936: Hyperkalemic Mineralocorticoid Resistance -	• • • •
C4049702: Focal	Segmental Glomerulosclerosis, Not Otherwise Specified C0017919: Glycogen Storage Disease	•••••
	C0029866: Other ureteric obstruction -	• • • • •
	C4552839: Hypomagnesemia, CTCAE C0854917: Rhabdoid Tumor of the Kidney	• • • •
	C0001126: Renal tubular acidosis	• • • •
	C0004775: Bartter Disease - C0268450: Gitelman Syndrome -	• • •
C0	085548: Autosomal Recessive Polycystic Kidney Disease	•• • •
	C0431718: Multiple renal cysts C0028734: Nocturia -	• • ••
	C0028734: Nocturia - C1266043: Sarcomatoid Renal Cell Carcinoma -	• •• •
	C0220983: Metabolic alkalosis	• •••
	C0005944: Metabolic Bone Disorder - C3825201: Mitochondrial pathology -	• • •
	C0078911: AIDS-Associated Nephropathy	• • • •
	C0543800: ldiopathic hypercalciuria - C0268800: Simple renal cyst -	
	C0002063: Alkalosis	• • ••


b	Omic Social Soci
Omic	Species
Epiproteome C0042373: Vascular E	Diseases -
Proteome C1449563: Cardiomyopathy, Familial Id	iopathic -
Metagenome C3203102: Idiopathic pulmonary arterial hyper Metabolome C0011853: Diabetes Mellitus, Exper	
Metabolome C0011853: Diabetes Mellitus, Exper Epigenome C0002895: Anemia, Sic	
Species C0856169: Endothelial dys	
Mouse C0011884: Diabetic Reti	
Rat C0155626: Acute myocardial in C0151786: Muscle W	
Exposure C0007787: Transient Ischemi	
Spaceflight C0151744: Myocardial Is	schemia -
GCRsim C0162871: Aortic Aneurysm, Ab MGsim	
C0007785: Cerebral In Sample C0271650: Impaired glucose to	
Kidney C0020557: Hypertriglyce	
Plasma C2973725: Pulmonary arterial hype	
Faeces C0013274: Patent ductus ar C0020459: Hyperin:	
C0020445: Hypercholesterolemia,	
C0085096: Peripheral Vascular D	
LogP C0003811: Cardiac Arri	
4 C0149721: Left Ventricular Hype 8 12 C0020473: Hyperli	
12 16 C0740391: Middle Cerebral Artery O	
20 C0020443: Hypercholeste 24	
C0577631: Carotid Atheros C0948089: Acute Coronary Sy	
C0598608: Hyperhomocyst	
C1704272: Benign Prostatic Hyp	erplasia - 🔹 🔹 🔹 🔹 🔹 🗳 🗳 🔹 🔹 🔹
0.16 C0242339: Dyslip	
C0018799: Heart E - 0.14 C1861172: Venous Thromboer	
C0024138: Lupus Erythematosus,	
- 0.12 C0007766: Intracranial Ar	
C0004943: Behcet Sy	
C0007786: Brain Is C1704436: Peripheral Arterial D	
C1704436: Peripheral Arterial C C024131: Lupus C024131: Lupus C0947751: Vascular inflam	Vulgaris - • • • • • • • • • • • •
C0745103: Hyperlipoproteinemia C0007820: Cerebrovascular D	
C0007194: Hypertrophic Cardiom	
- 0.04 C0018784: Sensorineural Hearing Loss (d	isorder) - • • • • • • • • • • • •
C4703473: Atheroscleroti	
C0398623: Throm C0005779: Blood Coagulation D	
C0011644: Scler	
C0005940: Bone E	
C0035126: Reperfusio C0011175: Deh	
C0011175: Deh C0042870: Vitamin D De	
C0751406: Post-Traumatic Osteo	
C0202236: Triglycerides measu	
C1445957: Serum total cholesterol measu C0852036: Pregnancy associated hype	
C0740392: Infarction, Middle Cerebra	
C0086981: Sicca Sy	
C3539781: Progressive C0853897: Diabetic Cardiomyc	
C0023212: Left-Sided Hear	
C0018798: Congenital Heart	Defects • • • • • • • •
C0002152: Alloxan D	
C0038433: Streptozotocin E C0007282: Carotid S	
C1402315: Vascular	
C0541794: Skeletal muscle	
C0342649: Vascular calc C4732730: Blo	
C0151449: Primary Sjögren's sy	
C0428883: Diastolic blood p	
C0202117: Low density lipoprotein cholesterol measu C0003486: Aortic Ar	
C0003486: Aortic Ar C0024523: Malabsorption Sy	-
C4551472: Hypertrophic obstructive cardiom	
C0741923: cardia	
C0003857: Congenital arteriovenous malfo C0410158: Muscle (
C0279680: Transitional cell carcinoma of	-
C0036529: Myocardial Diseases, Se	
C1867743: Premature coronary artery atheros C0241005: Creatine phosphokinase serum in	
C0241005: Creatine phosphokinase serum in C1397307: Cardiac	
C1868938: End stage cardia	c failure - 🔹 🔹 🔹 🔹 🔹
C0035579: C4049796: Abnormality of cardiovascular system mor	
C4049796: Abnormality of cardiovascular system mor C0856742:	
C4049446: Neointimal hyp	
C0428474: Serum LDL cholesterol measu	
C2937421: Prostatic Hyp C1135196: Heart Failure, I	
C2827469: Coronary Microvascular	
C1145628: Autonomic nervous system d	
C0037889: Hereditary spher	
C0005823: Blood F C3825201: Mitochondrial pa	
C0156149: Gastrointestinal tract vascular insuf	57
C2004435: Vascular insufficiency of i	
C2004435: Vascular insufficiency of i C0242231: Coronary 9	Stenosis - • •
C2004435: Vascular insufficiency of i	isorder) - • •

С	Ex	
	proteome C4529962: Fatty Liver Disease	
Trar	teome C0030297: Pancreatic Neoplasm nscriptome C0026838: Muscle Spasticity	
Met	tagenome C0025838: Muscle Spasticity tabolome C0025286: Meningioma genome	
Species	C0494463: Alzheimer Disease, Late Onset C0032580: Adenomatous Polyposis Coli	
Mo	man C0555196: Malignant Giloma	
Rat	t C4721453: Peripheral Nervous System Diseases C0153381: Malignant neoplasm of mouth	
	aceflight CO278510, Childhead Madullahlastama	
GC	Rsim C0162429: Malnutrition	
Sample	Ssim C0024305: Lymphoma, Non-Hodgkin C0011615: Dermatitis, Atopic	
Kid	ema	
	c4551683: Adrenal Gland Pheochromocytoma	
	C3887461: Head and Neck Carcinoma C0220641: Lip and Oral Cavity Carcinoma	
	C0220641: Lip and Oral Cavity Careinoma C0521158: Recurrent tumor	
-LogP 4	C0002793: Anaplasia C0030305: Pancreatitis	
• 8 • 12	C0019158: Hepatitis	•• • • ••••••• ••
16 20		
	C1762616: Meningioma, benign, no ICD-O subtype	
	C0278877: Adult Meningioma C1257931: Mammary Neoplasms, Human	
0.14	C4704874: Mammary Carcinoma, Human C0010823: Cytomegalovirus Infections	
0.14	C0023493: Adult T-Cell Lymphoma/Leukemia	•••• •••
- 0.12	C4086152: Childhood Astrocytoma C0153690: Secondary malignant neoplasm of bone	
	C0024667: Animal Mammary Neoplasms	••••
- 0.10	C1257925: Mammary Carcinoma, Animal C1328504: Hormone refractory prostate cancer	
- 0.06		•••••
	C0374997: Helicobacter pylori (H. pylori) infection C0007124: Noninfiltrating Intraductal Carcinoma C0238198: Gastrointestinal Stromal Tumors	
- 0.06	C0019348: Herpes Simplex Infections	
	C0278488: Carcinoma breast stage IV	• • • • • • • • • • • •
- 0.04	C0023487: Acute Promyelocytic Leukemia C0282193: Iron Overload	
- 0.02	C0026837: Muscle Rigidity C0345967: Malignant mesothelioma	
	CU345967: Malignant mesothelioma C1708349: Hereditary Diffuse Gastric Cancer	
	C0206754: Neuroendocrine Turnors C0039101: synovial sarcoma	
	C0019159: Hepatitis A	• • • • • • • • • • • • • • • • • • • •
	C0020615: Hypoglycemia C0853879: Invasive carcinoma of breast	
	C0024668: Mammary Neoplasms, Experimental	
	C0279671: Cervical Squamous Cell Carcinoma C4721806: Carcinoma, Basal Cell	
	C4551686: Malignant neoplasm of soft tissue C0025500: Mesothelioma	
	C0016057: Fibrosarcoma	•••••
	C0023267: Fibroid Tumor C0008479: Chondrosarcoma	
	C0553580: Ewings sarcoma C0008354: Cholera	
	C0281361: Adenocarcinoma of pancreas	
	C0151779: Cutaneous Melanoma C0007113: Rectal Carcinoma	
	C0037274: Dermatologic disorders	• • • • • • • • • • • • • • • •
	C0086692: Benign Neoplasm C0333463: Senile Plaques	
	C0014556: Epilepsy, Temporal Lobe C0278883: Metastatic melanoma	
	C0205698: Undifferentiated carcinoma	• • • • • • • • • • • • • • • • • • • •
	C1134719: Invasive Ductal Breast Carcinoma C4733092: estrogen receptor-negative breast cancer	
	C0153452: Malignant neoplasm of gallbladder	
	C0345905: Intrahepatic Cholangiocarcinoma C2938924: Oestrogen receptor positive breast cancer	
	C4721579: Secondary malignant neoplasm of colon and/or rectum C3495559: Juvenile arthritis	
	C2062441: Influenza A	• • • • • • • • • • • • • • •
	C0006111: Brain Diseases C0206708: Cervical Intraepithelial Neoplasia	
	C0003130: Anoxia	
	C0238461: Anaplastic thyroid carcinoma C0206686: Adrenocortical carcinoma	• • • • • • • • • •
	C0162557: Liver Failure, Acute C0031511: Pheochromocytoma	
	C0747845: early pregnancy	• • • • • • • • •
	C0007112: Adenocarcinoma of prostate C3900098: Adult Myelodysplastic Syndrome	
	C2347761: Childhood Myelodysplastic Syndrome	• • • • • • • • • •
	C0238462: Medullary carcinoma of thyroid C0940937: precancerous lesions	
	C0205647: Follicular adenoma C0021670: insulinoma	
	C0205696: Anaplastic carcinoma	••••
	C0279550: Adult Rhabdomyosarcoma C0220611: Childhood Rhabdomyosarcoma	
	C0035412: Rhabdomyosarcoma C0008350: Cholelithiasis	
	C0006413: Burkitt Lymphoma	

d		
Omic	Exp	
Epiproteome Proteome	C0004936: Mental disorders	•••••
Transcriptome	C0149931: Migraine Disorders C0038525: Subarachnoid Hemorrhage	
Metagenome Metabolome	C0024115: Lung diseases	•••••••••••••
Epigenome	C0011265: Presenile dementia	•••••
Species Mouse	C0085207: Gestational Diabetes C0085584: Encephalopathies	•• ••••
Human Rat	C0011991: Diarrhea	•••• • ••••••••
Exposure	C0040822: Tremor C0015672: Fatigue	
Spaceflight simGCRsim	C0234985: Mental deterioration	•••• • ••••••• •••
GCRsim MGsim	C0242422: Parkinsonian Disorders	
Sample	C0041696: Unipolar Depression C0013080: Down Syndrome	
Kidney Plasma	C0020676: Hypothyroidism	•• •• ••••••••
Exosome Faeces	C0009806: Constipation C0017601: Glaucoma	
	C0008370: Cholestasis	•••• • •• ••••
	C4521042: Complete Trisomy 21 Syndrome C1963184: Nystagmus, CTCAE 3.0	
11	C4554036: Nystagmus, CTCAE 5.0	•• •••
-LogP -LogP • 4	C1384666: hearing impairment C0151889: Hyperreflexia	
• 8	C0233794: Memory impairment	•• •• ••• •••• •
 12 16 	C0033975: Psychotic Disorders	
• 20	C0525045: Mood Disorders C0235946: Cerebral atrophy	••••••••••••••••••••••••••••••••••••••
	C0038002: Splenomegaly	••••
	C0008626: Congenital chromosomal disease	
	C0339573: Glaucoma, Primary Open Angle	• • • • • • • • • • • • • •
- 0.12	C0006287: Bronchopulmonary Dysplasia C3714636: Pneumonitis	· · · · · · · · · · · · · · · · · · ·
	C3714636: Pneumonitis C0022104: Irritable Bowel Syndrome	••••
- 0.10	C0038436: Post-Traumatic Stress Disorder	•••••
	C0037284: Skin lesion C0374997: Helicobacter pylori (H. pylori) infection	
- 0.01	C0027092: Myopia	• • • • • • • • • • • • • • •
Buich Enrich Enrich	C0001973: Alcoholic Intoxication, Chronic C0018818: Ventricular Septal Defects	
Е - 0.06	C0026650: Movement Disorders	•• •• • •••• • ••••
	C0020550: Hyperthyroidism C0013264: Muscular Dystrophy, Duchenne	
- 0.04	C0432072: Dysmorphic features	• • • • • • • • • • • •
	C1270972: Mild cognitive disorder	••••
- 0.02	C0022821: Kyphosis deformity of spine C0542476: Forgetful	••••• ••••••••••
	C1861403: Variable expressivity	•• ••• • • •••• •
	C2826323: Refractory Cytopenia of Childhood C0013421: Dystonia	· · · · · · · · · · · · · · · · · · ·
	C0026848: Myopathy	•• •• • •••• •
	C4553743: Spasticity, CTCAE C0040034: Thrombocytopenia	
	C0042133: Uterine Fibroids	•• •••••
	C0035229: Respiratory Insufficiency C0017168: Gastroesophageal reflux disease	
	C0175754: Agenesis of corpus callosum	• • • • • • • • • • • •
	C0025362: Mental Retardation	•••••
	C0020534: Orbital separation excessive C0520679: Sleep Apnea, Obstructive	
	C0009241: Cognition Disorders	•••• • • • • •
	C0003504: Aortic Valve Insufficiency C0036857: Severe intellectual disability	
	C0019294: Hernia, Inguinal	• • • • • • • • • • • •
	C0007193: Cardiomyopathy, Dilated C0007758: Cerebellar Ataxia	
	C0007758: Cerebeliar Ataxia C0038013: Ankylosing spondylitis	• • • • • • • • • • •
	C0442874: Neuropathy C0005699: Blast Phase	••••••••
	C0005699: Blast Phase C0276496: Familial Alzheimer Disease (FAD)	••••
	C0027947: Neutropenia	••••••••
	C0002170: Alopecia C0151611: Electroencephalogram abnormal	
	C3665347: Visual Impairment	• • • • • • • • • • • • • • • •
	C0010417: Cryptorchidism C0232466: Feeding difficulties	
	C1535926: Neurodevelopmental Disorders	• •• •• • • •• •
	C1145670: Respiratory Failure C0011168: Deglutition Disorders	· · · · · · · · · · · ·
	C0269102: Endometrioma	• • • • • • • • •
	C0020255: Hydrocephalus C0018817: Atrial Septal Defects	
	C0018817: Atrial Septal Defects C0000737: Abdominal Pain	• • • • • • • • • • •
	C0949664: Tauopathies	• • • • • • • • • • •
	C0235833: Congenital diaphragmatic hernia C0424605: Developmental delay (disorder)	
	C0524528: Pervasive Development Disorder	••••
	C0020429: Hyperalgesia C0028945: oligodendroglioma	
	C1857276: Trichohepatoenteric Syndrome	•••••••••
	C0027962: Melanocytic nevus C0375023: Respiratory syncytial virus (RSV) infection	
	C0026850: Muscular Dystrophy	••••
	C0009081: Congenital clubfoot	• •• •••
	C0206062: Lung Diseases, Interstitial C0851578: Sleep Disorders	
	C0006012: Borderline Personality Disorder	••••
	C0151468: Thyroid Gland Follicular Adenoma	
	C0038379: Strabismus	•• ••• • • ••
1		


Supplementary Figure 3: Faecal Microbiome KEGG pathway over-representation analysis results

The top enriched KEGG microbiome pathway ontological terms. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value (no enrichment scores could be calculated). A Log10(P-value) of 1.3 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Plant-related terms removed from the display.




Supplementary Figure 4: Multi-omic KEGG pathway over-representation analysis top results by category grouping

The top 100 enriched KEGG pathway ontological terms relating to **a**, kidney health or cellular injury/stress, b, closely related to kidney injury and disease [vasculature; blood pressure; bone; muscle; diabetes] remodelling, c, no clear connection to the kidney, are presented. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.q. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A Log10(P-value) of 2 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.



hsa00190: Oxidative phosphorylation hsa00480: Glutathione metabolism hsa04022: cGMP-PKG signaling pathway hsa04066: HIF-1 signaling pathway

- hsa00620: Pyruvate metabolism
- hsa04140: Autophagy animal
- hsa04926: Relaxin signaling pathway hsa04010: MAPK signaling pathway
 - hsa04024: cAMP signaling pathway
 - hsa04210: Apoptosis -
- hsa04152: AMPK signaling pathway hsa04150: mTOR signaling pathway -
- hsa04962: Vasopressin-regulated water reabsorption hsa04668: TNF signaling pathway
 - hsa04924: Renin secretion -
 - hsa04068: FoxO signaling pathway -
 - hsa04614: Renin-angiotensin system hsa05211: Renal cell carcinoma -
 - hsa00020: Citrate cycle (TCA cycle) -
 - hsa04966: Collecting duct acid secretion -
- hsa04964: Proximal tubule bicarbonate reclamation
- hsa04960: Aldosterone-regulated sodium reabsorption




GCRsim

MGsim

Exosome

Faeces



Metagenome

Metabolome

Rat

Epigenome



b

Omic

Epiproteome

Transcriptome

Proteome

С	O Spor Epor Tra	
	hsa05022: Pathways of neurodegeneration - multiple diseases -	
	hsa05020: Prion disease -	• • • • • • • • • •
	hsa05208: Chemical carcinogenesis - reactive oxygen species	••••••
Omic	hsa05200: Pathways in cancer hsa05012: Parkinson disease -	•• •• •
Epiproteome Proteome	hsa05016: Huntington disease -	•• •• • • • • • •
Transcriptome	hsa05165: Human papillomavirus infection - hsa05010: Alzheimer disease -	
Metagenome Metabolome	hsa05171: Coronavirus disease - COVID-19 -	
Epigenome	hsa05415: Diabetic cardiomyopathy	•• •• •• •• •
Species	hsa04714: Thermogenesis hsa05132: Salmonella infection -	••••••••••••••••••••••••••••••••••••••
Mouse	hsa04144: Endocytosis -	••••
Human Rat	hsa05205: Proteoglycans in cancer - hsa05014: Amyotrophic lateral scierosis -	
Exposure	hsa01200: Carbon metabolism	
Spaceflight	hsa04723: Retrograde endocannabinoid signaling -	• • • • • • • •
simGCRsim GCRsim	hsa04910: Insulin signaling pathway - hsa03320: PPAR signaling pathway -	• • • • • • • •
MGsim	hsa05163: Human cytomegalovirus infection -	••••
Sample	hsa05166: Human T-cell leukemia virus 1 infection - hsa04915: Estrogen signaling pathway -	
Kidney Plasma	hsa05146: Amoebiasis	• • • • • • • •
Exosome	hsa04974: Protein digestion and absorption	• • • • • • •
Faeces	hsa04141: Protein processing in endoplasmic reticulum - hsa04145: Phagosome -	
	hsa05130: Pathogenic Escherichia coli infection	••••
	hsa00983: Drug metabolism - other enzymes - hsa05131: Shigellosis -	
	hsa04934: Cushing syndrome -	• • • • • • •
	hsa04360: Axon guidance	• • • • • • •
LogP 15	hsa04932: Non-alcoholic fatty liver disease - hsa01240: Biosynthesis of cofactors -	···· · ···
 30 45 	hsa05215: Prostate cancer	• • • • • • •
60	hsa05202: Transcriptional misregulation in cancer - hsa05135: Yersinia infection -	• • • • • •
	hsa00280: Valine, leucine and isoleucine degradation -	• • •
	hsa05203: Viral carcinogenesis hsa05225: Hepatocellular carcinoma -	•••••
	hsa04921: Oxytocin signaling pathway -	• • • • • •
	hsa04922: Glucagon signaling pathway	••••
	hsa04142: Lysosome - hsa04713: Circadian entrainment -	
	hsa05416: Viral myocarditis -	•• •••
- 0.08	hsa04927: Cortisol synthesis and secretion - hsa04261: Adrenergic signaling in cardiomyocytes -	· · · · · ·
	sa05120: Epithelial cell signaling in Helicobacter pylori infection -	
- 0.06 ueu	hsa04621: NOD-like receptor signaling pathway	• • ••• •
-0.06 urichmen -0.04	hsa01524: Platinum drug resistance - hsa04918: Thyroid hormone synthesis -	
-0.04 🗳	hsa03010: Ribosome	••••
	hsa05150: Staphylococcus aureus infection - hsa04371: Apelin signaling pathway -	••• •• •
- 0.02	hsa04931: Insulin resistance -	•••
	hsa04670: Leukocyte transendothelial migration -	• • • • •
	hsa04919: Thyroid hormone signaling pathway hsa04913: Ovarian steroidogenesis -	• • • • • • •
	hsa00650: Butanoate metabolism -	• • • • •
	hsa05152: Tuberculosis - hsa05231: Choline metabolism in cancer -	
	hsa05207: Chemical carcinogenesis - receptor activation -	• • • •••
	hsa05134: Legionellosis - hsa05170: Human immunodeficiency virus 1 infection -	• ••• • •
	hsa04666: Fc gamma R-mediated phagocytosis -	• • • • •
	hsa00590: Arachidonic acid metabolism -	• • • ••
	hsa05230: Central carbon metabolism in cancer hsa04146: Peroxisome -	
	hsa00380: Tryptophan metabolism -	• • • • •
	hsa01212: Fatty acid metabolism - hsa03040: Spliceosome -	
	hsa05204: Chemical carcinogenesis - DNA adducts -	• • •
	hsa00980: Metabolism of xenobiotics by cytochrome P450 - hsa04976: Bile secretion -	• • • •
	nsau4970: Bile secretion - hsa04211: Longevity regulating pathway -	• • • •
	hsa05100: Bacterial invasion of epithelial cells	• • • •
	hsa04213: Longevity regulating pathway - multiple species - hsa04080: Neuroactive ligand-receptor interaction -	•••••
	hsa04260: Cardiac muscle contraction -	• • • • •
	hsa05167: Kaposi sarcoma-associated herpesvirus infection - hsa00030: Pentose phosphate pathway -	• • •
	hsa05110: Vibrio cholerae infection	••• • •
	hsa04935: Growth hormone synthesis, secretion and action - hsa04216: Ferroptosis -	• • • • •
	hsa00051: Fructose and mannose metabolism	• • • •
	hsa04728: Dopaminergic synapse	• • • • •
	hsa04725: Cholinergic synapse - hsa04071: Sphingolipid signaling pathway -	
	hsa05213: Endometrial cancer -	• • • • •
	hsa01232: Nucleotide metabolism - hsa05214: Glioma -	• • • •
	hsa05220: Chronic myeloid leukemia	• • • •
	hsa04657: IL-17 signaling pathway -	••• • •
	hsa05164: Influenza A - hsa04973: Carbohydrate digestion and absorption -	• • • •
	hsa00071: Fatty acid degradation	• • ••
	hsa05017: Spinocerebellar ataxia - hsa04613: Neutrophil extracellular trap formation -	• • •
	hsa04013: Neudoprin exclacential dap formation - hsa04710: Circadian rhythm -	• • •
	hsa04916: Melanogenesis hsa05224: Breast cancer	• • • •
	nsauu224: Breast cancer -	R410 R42,20 R42,20 R42,20 R42,20 R42,10 R42,
		9110 814.23 NSR.224/97 NSR.224/97 NSR.224/97 NS.224/97 NSR.244/97 NSR.244/97

Supplementary Figure 5: Multi-omic Gene Ontology (GO) over-representation analysis top results by category grouping

The top 100 enriched GO ontological terms relating to **a**, biological process, **b**, cellular component **c**, molecular function are presented. These were ranked and represented in descending order using the following rules: 1) No. of mission datasets it replicated in; 2) most significant p-value; 3) greatest enrichment. To integrate datasets from different omics modalities, species, missions and tissues, all biomolecules (e.g. phosphopeptides, proteins, transcripts and methylated DNA) were converted to the human orthologs where necessary and linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites). A Log10(P-value) of 2 was considered significant for ontological term enrichment and had to replicate in at least two datasets to be plotted. Enrichment ratio; the number of differentially regulated hits in a dataset that belong to a given ontological term, normalised to the total number of statistically significant hits in the respective dataset.

а	Spe Export	
Omia	GO:0031589: cell-substrate adhesion -	•••
Omic Epiproteome	GO:0045785: positive regulation of cell adhesion	•••
Proteome Transcriptome	GO:0006979: response to oxidative stress	•• • • • • •
Metagenome Metabolome	GO:0050920: regulation of chemotaxis GO:0045861: negative regulation of proteolysis	
Epigenome	GO:0072521: purine-containing compound metabolic process	•••••
Species	GO:0009117: nucleotide metabolic process - GO:0006753: nucleoside phosphate metabolic process -	· · · · · · · · ·
Mouse	GO:0006163: purine nucleotide metabolic process	•••••
Rat	GO:0001655: urogenital system development	•• • • • • • •
Exposure	GO:0006091: generation of precursor metabolites and energy GO:0043254: regulation of protein-containing complex assembly-	
Spaceflight simGCRsim	GO:0010810: regulation of protein containing complex assembly - GO:0010810: regulation of cell-substrate adhesion -	• • • • • • • • •
GCRsim	GO:0015711: organic anion transport	•••
MGsim	GO:0006869: lipid transport GO:0010876: lipid localization -	
Sample Kidney	GO:0032103: positive regulation of response to external stimulus -	•• ••••
Plasma	GO:0030900: forebrain development	• • • • • • • •
Exosome Faeces	GO:0007160: cell-matrix adhesion - GO:0052548: regulation of endopeptidase activity -	
	GO:0070372: regulation of ERK1 and ERK2 cascade	• • • • • • • •
	GO:0033157: regulation of intracellular protein transport	••• • • • • • •
	GO:0010811: positive regulation of cell-substrate adhesion - GO:0007611: learning or memory -	
-LogP	GO:0046394: carboxylic acid biosynthetic process	• ••• • ••• •
• 6 • 12	GO:0016053: organic acid biosynthetic process -	• • • • • • • •
18 24	GO:0009150: purine ribonucleotide metabolic process - GO:0009259: ribonucleotide metabolic process -	• •• ••• •
30	GO:0019693: ribose phosphate metabolic process	•• ••
	GO:0072001: renal system development	•• • •••
	GO:0001822: kidney development - GO:0022411: cellular component disassembly -	
	GO:0022411: celular component disassembly GO:0050808: synapse organization -	•• • •• •• •
0.10	GO:0031346: positive regulation of cell projection organization -	••••••••
	GO:0009410: response to xenobiotic stimulus - GO:0046034: ATP metabolic process -	
	G0:0032386: regulation of intracellular transport -	•••
- 0.08	GO:0031647: regulation of protein stability	•• ••• • •• •
	GO:2001233: regulation of apoptotic signaling pathway - GO:0042060: wound healing -	
	GO:0042060: Wound healing GO:0016042: lipid catabolic process -	• • • • • • • •
- 0.06	GO:0019216: regulation of lipid metabolic process	•• ••••
- 0.06 Eurichmen	GO:0010038: response to metal ion -	•• ••• •
Enri	GO:0007409: axonogenesis GO:0015849: organic acid transport	• • • • • •
- 0.04	GO:0072594: establishment of protein localization to organelle -	••• •• •• •
0.04	G0:0042176: regulation of protein catabolic process	•• • ••• •
	GO:0048638: regulation of developmental growth - GO:0051235: maintenance of location -	
- 0.02	GO:0071900: regulation of protein serine/threonine kinase activity -	• • • • • • •
-0.02	GO:0097193: intrinsic apoptotic signaling pathway-	•• •• •••
	GO:0030099: myeloid cell differentiation - GO:0022407: regulation of cell-cell adhesion -	• • • • • • • • •
	GO:0046942: carboxylic acid transport	•••
	GO:0061041: regulation of wound healing	•• • •• •••
	GO:0034599: cellular response to oxidative stress GO:0070371: ERK1 and ERK2 cascade -	• • • • • • • •
	GO:0052547: regulation of peptidase activity	• • • • • • •
	GO:0043491: protein kinase B signaling	• • •• ••
	GO:0006090: pyruvate metabolic process - GO:0021537: telencephalon development -	· · · · · · · ·
	G0:0000302: response to reactive oxygen species	••••
	GO:0016052: carbohydrate catabolic process -	••••
	GO:0050890: cognition - GO:0050921: positive regulation of chemotaxis -	•••••••
	GO:0051604: protein maturation -	• • • • • • • •
	GO:0051896: regulation of protein kinase B signaling	• • ••• ••
	GO:1902903: regulation of supramolecular fiber organization -	
	GO:0034329: cell junction assembly GO:0006631: fatty acid metabolic process -	· · · · · · · · · · · · · · · · · · ·
	GO:0044282: small molecule catabolic process	• • • • • • •
	GO:0010639: negative regulation of organelle organization	••••
	GO:0072330: monocarboxylic acid biosynthetic process - GO:0008202: steroid metabolic process -	
	GO:0002181: cytoplasmic translation -	•• •••
	GO:0045765: regulation of angiogenesis	• • • • • •
	GO:1901342: regulation of vasculature development - GO:1903829: positive regulation of protein localization -	
	GO:0001667: ameboidal-type cell migration	•• • • ••
	GO:0034504: protein localization to nucleus	••••
	GO:0006820: anion transport - GO:0010563: negative regulation of phosphorus metabolic process -	
	GO:0045936: negative regulation of phosphate metabolic process GO:0045936: negative regulation of phosphate metabolic process	•• • • • • •
	GO:0022604: regulation of cell morphogenesis	•• • • • ••
	GO:0019439: aromatic compound catabolic process - GO:0010631: epithelial cell migration -	•••••
	GO:0090132: epithelium migration -	•• •••
	G0:0090130: tissue migration -	•• •••
	GO:0050878: regulation of body fluid levels - GO:0032869: cellular response to insulin stimulus -	
	GO:0032869: cellular response to insulin stimulus - GO:1903034: regulation of response to wounding -	• • • • •
	GO:0010632: regulation of epithelial cell migration	•• •• •• •
	GO:0062197: cellular response to chemical stress -	
	G0:0051348: negative regulation of transferase activity - G0:0034248: regulation of cellular amide metabolic process -	
	G0:0030336: negative regulation of cell migration -	• • • • • • •
	GO:0003012: muscle system process	• • • • • • •
	GO:1900180: regulation of protein localization to nucleus - GO:0010594: regulation of endothelial cell migration -	
	GO:0051346: negative regulation of hydrolase activity	• • •••• •


h			
D			
Omic	GO:0045177: apical part of cell-		•
Epipro			•
Trans	GO:0062023: collagen-containing extracellular matrix -		••
Metag Metab	GO:0005903: brush border	••••	
Epige	n G0:0043209: myelin sheath - G0:0098978: glutamatergic synapse -		•
Species Mous	GO:0005743: mitochondrial inner membrane -	• • • • • • •	• •
Huma Rat	GO:0016324: apical plasma membrane -		
	GO:0031968: organelle outer membrane -	•• • • ••••	•
Exposure Space	GO:0001726: ruffle - e! GO:0030016: myofibril -		
simG	C GO:0043393: contractile fiber-	•• • •••	• •
MGsi	rr GO:0098862: cluster of actin-based cell projections - GO:0005604: basement membrane -		
Sample	GO:0098857: membrane microdomain -	• • • • • •	••
Plasn	GO:0005769: early endosome -		• •
Exos Faece	5	• • • • • •	•
	GO:0032279: asymmetric synapse - GO:0098984: neuron to neuron synapse -		•
	G0:009995: basal plasma membrane -	•••••	•
	G0:0005844: polysome -		• •
-LogP 8	GO:0030017: sarcomere - GO:0098793: presynapse -	•• •• •	•
• 16	GO:0044391: ribosomal subunit -		•
● 24 ● 32	GO:0005840: ribosome - GO:0005938: cell cortex -		•
	GO:0099572: postsynaptic specialization -	• • • • •	•
	GO:0005912: adherens junction - GO:0098798: mitochondrial protein-containing complex -		•
	GO:0045178: basal part of cell	••	
0.10	GO:0005874: microtubule - GO:0042383: sarcolemma -		
	G0:0005635: nuclear envelope	••••	
	GO:0016528: sarcoplasm -		
- 0.08	GO:0036464: cytoplasmic ribonucleoprotein granule - GO:1990204: oxidoreductase complex -		••••
	G0:0031526: brush border membrane	•••	
	GO:0035770: ribonucleoprotein granule - GO:1905369: endopeptidase complex -		••
- 0.06	GO:0005741: mitochondrial outer membrane -		•
	GO:0071013: catalytic step 2 spliceosome - GO:0043230: extracellular organelle -		•
	GO:0065010: extracellular membrane-bounded organelle	• • •	•
- 0.04	GO:0070062: extracellular exosome - GO:0031301: integral component of organelle membrane -		•
	GO:1903561: extracellular vesicle	• • • • • • •	•
- 0.02	GO:0022626: cytosolic ribosome		•
0.02	GO:0015934: large ribosomal subunit GO:0022625: cytosolic large ribosomal subunit -		•
	GO:0014069: postsynaptic density		•
	GO:0016607: nuclear speck - GO:0005925: focal adhesion -		•
	GO:0032432: actin filament bundle	•••	•
	GO:0042641: actomyosin - GO:0030018: Z disc -		•
	GO:0016323: basolateral plasma membrane	• • • • •	
	- GO:0031674: I band GO:0042788: polysomal ribosome		•
	GO:0001725: stress fiber	• • • •	•
	GO:0097517: contractile actin filament bundle - GO:0022627: cytosolic small ribosomal subunit -		•
	GO:0005759: mitochondrial matrix -	• • •	•
	GO:0030427: site of polarized growth - GO:0070469: respirasome -		•
	G0:0030139: endocytic vesicle -		
	GO:0005746: mitochondrial respirasome - GO:0098858: actin-based cell projection -		•
	GO:00098838: actin-based cell projection - GO:0005681: spliceosomal complex -		•
	GO:0098803: respiratory chain complex -		•
	GO:0140534: endoplasmic reticulum protein-containing complex - GO:0090575: RNA polymerase II transcription regulator complex -		••
	GO:0043235: receptor complex	• • • •	•
	GO:0005581: collagen trimer- GO:0097060: synaptic membrane-	••••	•
	GO:1905368: peptidase complex -	• • •	••
	GO:1990351: transporter complex - GO:0005901: caveola -	- • • •	• •
	GO:0016328: lateral plasma membrane -	• • • • •	
	G0:0031300: intrinsic component of organelle membrane - G0:0030027: lamellipodium -		
	GO:0030055: cell-substrate junction	• • •	•
	GO:0015935: small ribosomal subunit - GO:0043296: apical junction complex -		• •
	GO:0030863: cortical cytoskeleton	• • • •	
	GO:1902911: protein kinase complex - GO:0016529: sarcoplasmic reticulum -		•
	G0:0016529: sarcoplasmic reticulum - G0:0030864: cortical actin cytoskeleton -		
	GO:0150034: distal axon	• •	•
	GO:0098800: inner mitochondrial membrane protein complex - GO:0010008: endosome membrane -	• • •	•
	G0:0005777: peroxisome	• • • •	
	GO:0042579: microbody - GO:0005790: smooth endoplasmic reticulum -		
	GO:0030426: growth cone	• •	•
	GO:0061695: transferase complex, transferring phosphorus-containing groups - GO:0032587: ruffle membrane -		•
	GO:0005788: endoplasmic reticulum lumen -		

С	0 See	mic			
•	Expos Sam				
Omic	GO:0003779: actin binding	••	•••	• • • • • •	
Epiproteome Proteome	GO:0004857: enzyme inhibitor activity GO:0050839: cell adhesion molecule binding	•••	•	•••••	•
Transcriptom	e GO:1901681: sulfur compound binding	•	•	• • • • • • • •	
Metabolome	GO:0008201: heparin binding	•		• • • • • • •	
Epigenome	GO:0003712: transcription coregulator activity GO:0022853: active ion transmembrane transporter activity	••	•	•••••	
Species Mouse	GO:0005539: glycosaminoglycan binding	-		• •••• ••	
Human	GO:0044389: ubiquitin-like protein ligase binding GO:0031406: carboxylic acid binding	••	••	••••	
Rat	GO:0031406: Carboxylic acid binding GO:0046943: carboxylic acid transmembrane transporter activity	•••		••••	
Exposure Spaceflight	GO:0005342: organic acid transmembrane transporter activity	• •	•	••••	
simGCRsim	GO:0031625: ubiquitin protein ligase binding RNA polymerase II-specific DNA-binding transcription factor binding :	••	••	••• •	
GCRsim MGsim	GO:0033293: monocarboxylic acid binding		• •		
Sample	GO:0061134: peptidase regulator activity		•	••• •••	•
Kidney Plasma	GO:0051015: actin filament binding GO:0016614: oxidoreductase activity, acting on CH-OH group of donors			• • • •	
Exosome	GO:0005201: extracellular matrix structural constituent	•		••••	
Faeces	GO:0003713: transcription coactivator activity GO:0022804: active transmembrane transporter activity	••	•	• • • •	
	GO:0005178: integrin binding	•			
	GO:0008509: anion transmembrane transporter activity GO:0019838: growth factor binding-	• •	•	••••	
-LogP	GO:0015636; growth ractor binning GO:0016887: ATP hydrolysis activity	••		• •	
• 20	GO:0008514: organic anion transmembrane transporter activity	• •		••••	
• 30 • 40	GO:0002020: protease binding GO:0003735: structural constituent of ribosome		•••	• • •	
50	GO:0016853: isomerase activity		• • •		
GC	:0016616: oxidoreductase activity, acting on the CH-OH group of donors GO:0046873: metal ion transmembrane transporter activity		•	• • • • •	
	GO:0040875: metal for transmentionale transporter activity	•	•		
	GO:0016829: lyase activity	•	••	• • •	
0.10	GO:0051087: chaperone binding GO:0015291: secondary active transmembrane transporter activity		• •	•••	
	GO:0005525: GTP binding	•	• •	• • •	
	GO:0019001: guanyl nucleotide binding GO:0032561: guanyl ribonucleotide binding	•	• •	• • •	
- 0.08	G0:0005319: lipid transporter activity		•••		
	G0:0033218: amide binding	•	• •	•• •	
ť	GO:0019207: kinase regulator activity - GO:0042578: phosphoric ester hydrolase activity -	•••		•••••	
-0.06 En richment	GO:0043177: organic acid binding	•	•	•• • •	
Enric	GO:0004497: monooxygenase activity GO:0004866: endopeptidase inhibitor activity		• •	••••	
	GO:0045182: translation regulator activity	••	• •	• •	
- 0.04	GO:0016746: acyltransferase activity	•	•	• • • •	_
	GO:0061135: endopeptidase regulator activity GO:0003924: GTPase activity	•	• •		
- 0.02	GO:0004177: aminopeptidase activity	•	• •	• ••	
0.02	GO:0004860: protein kinase inhibitor activity GO:0015245: fatty acid transmembrane transporter activity	•••	•	••••	
	G0:0051020: GTPase binding	•		• • • •	
	GO:0004674: protein serine/threonine kinase activity GO:0005543: phospholipid binding-	•	•	••••	
	GO:0035091: phosphatidylinositol binding	•		• • • •	
	GO:0060090: molecular adaptor activity GO:0030674: protein-macromolecule adaptor activity	•••	•	•	
	GO:0050674: protein-macromolecule adaptor activity GO:0019903: protein phosphatase binding	•	•		
	GO:0016860: intramolecular oxidoreductase activity		•	• • • •	
	GO:0031072: heat shock protein binding GO:0051082: unfolded protein binding	•	•	• • •	
GG	0:0016627: oxidoreductase activity, acting on the CH-CH group of donors	•	•	• • •	
	GO:0015267: channel activity GO:0022803: passive transmembrane transporter activity			•• • • •	
	G0:0015081: sodium ion transmembrane transporter activity	•		• • • •	
	GO:0005216: ion channel activity			•• • • •	
	GO:0015293: symporter activity - GO:0008238: exopeptidase activity -		• •	•••	
	GO:0005261: cation channel activity	-		••••	
	GO:0022836: gated channel activity GO:0015370: solute:sodium symporter activity			••••	
	GO:0016709: oxidoreductase activity, acting on paired donors	-	•	••• •	
GO:00300	20: extracellular matrix structural constituent conferring tensile strength GO:0015294: solute:cation symporter activity			•••	
	G0:0015254: Solde:Catori sympoter activity G0:0005506: iron ion binding		• •	• • •	
	GO:0016289: CoA hydrolase activity	•		• • • •	
	GO:0016209: antioxidant activity GO:0046982: protein heterodimerization activity	• •	•	•••••	
	GO:0005080: protein kinase C binding	•		••• •	
	GO:0030414: peptidase inhibitor activity GO:0000287: magnesium ion binding-	••	•	• • • • •	
	GO:0050660: flavin adenine dinucleotide binding	•	•	•• •	
	GO:0020037: heme binding GO:0016791: phosphatase activity	••	•	••• •	
	GO:0090079: translation regulator activity, nucleic acid binding	••	•	• •	
	GO:0046332: SMAD binding-	1		• • • •	
	GO:0008028: monocarboxylic acid transmembrane transporter activity GO:0003714: transcription corepressor activity	•		• • • •	
	G0:0001221: transcription coregulator binding	••		• • •	
	GO:0047485: protein N-terminus binding GO:0043021: ribonucleoprotein complex binding	•	••	••••	
GO:0016747: a	cyltransferase activity, transferring groups other than amino-acyl groups	•	•	• ••	
	GO:0019210: kinase inhibitor activity GO:0030695: GTPase regulator activity	••		• • •	
	GO:0050695: GPase regulator activity GO:0060589: nucleoside-triphosphatase regulator activity	·		• • •	
	GO:0031267: small GTPase binding	•		• • •	
	GO:0005096: GTPase activator activity GO:0019902: phosphatase binding -	•••		• •	
	GO:0015631: tubulin binding	•		• • •	

GO:0015631: tubulin binding -• • ••


Supplementary Figure 6: qPCR of mitochondrial fission and fusion markers

a, Heatmap of mitochondrial fission and fusion mRNA transcript markers from RR-10 spaceflight-exposed mice (28 days) kidney tissue. **b**, Relative change in the geometric means of all fission or fusion markers. Data are mean ± 95% CI. A P-value of <0.05 was considered significant. **c**, Stability ranking of reference genes. **d**, Individual normalisation factors by animal. **e**, Mean relative difference in normalisation factor for groups. Data are mean ± range. A P-value of <0.05 was considered significant. **f**, RNA input vs relative reference gene levels.




Supplementary Figure 7: SPOKE Integrated knowledge network analysis


SPOKE (Scalable Precision Medicine Open Knowledge Environment) was used to integrate the heterogeneous data from several missions, experimental conditions, tissues, species and assay modalities. **a**, SPOKE workflow from inputs through to disease and anatomical associations, via convergent entry nodes for protein, gene, compound and organism nodes. **b**, Meta pathways to kidney disease (red nodes on the far right). Note the abundance of nodes associated with all of the inputting nodes, implying orthogonal confirmation across the inputted 18 -omics datasets of spaceflight conditions and renal pathology.



Supplementary Figure 8: Plasma miRNA Weighted Correlation Network Analysis (WGCNA)


Plasma miRNAs from BNL-1 simGCRsim-exposed mice (~1.5-year dose equivalent) for WGCNA. **a**, Dendrogram grouping miRNAs into three module-eigengenes (ME) according to co-expression profiles. **b**, Comparisons of ME's expression patterns in Sham vs GCR animals. Abundance heatmaps for constituent miRNAs in the ME are given in **c**, ME0, **d**, ME1, **e**, ME2.







а










e


Supplementary Figure 9: Kidney miRNA quantitative ISH

BNL-3 simGCRsim-exposed mouse (~1.5-year dose equivalent) kidney sections were stained for **a**, miR-16 and **b**, Let-7a. Data are mean \pm SD. A P-value of <0.05 was considered significant. OSOM; outer stripe of outer medulla. ISOM; inner stripe of outer medulla. IM; Inner medulla. Average; the simple arithmetic mean of the four anatomical regions.

miRNA-16




miRNA Let-7a





b

Supplementary Figure 10: Mouse plasma and urine physiological measurements

a, Urinary and **b**, plasma physiological measurements from NSRL22A GCRsim-exposed mice (~2.5-year dose equivalent). Boxed P-values report the two-way ANOVA treatment group factor result. Data are mean ± SD. A P-value of <0.05 was considered significant. FE; fraction excretion. Corr; corrected for albumin. Cr; creatinine. K; potassium. Mg; magnesium. Cl; chloride. KIM-1; kidney injury marker-1.







Supplementary Methods

Experimental Design, Considerations and Limitations

For all animal studies, only wildtype and untreated/vehicle control animals were used for data analysis. To maintain consistency and comparability, when studies had serial longitudinal measurements in both control and exposure-treated animals, the control and treatment groups were directly compared rather than comparing the differences from baseline. Where feasible to do so, persons involved in data acquisition or analysis were kept blinded to group identity to minimise the risk of investigator bias.

In the absence of in-flight measurements (L+ or FD+) we chose to look at post-flight (R+) timepoints as close to splashdown as possible to capture spaceflight phenomena with minimal influence from readaptation to microgravity.

Most spaceflight harvested samples would have gone through freeze-thaw cycles, however the quality of data was assessed, and any unsuitable datasets or samples were excluded on this technical basis. Another caveat that should be noted is that kidney that omics from RR-1, RR-3, RR-7, RR-23 animals were performed on different 1/6th portions cut from the kidney. While these portions likely came from the same anatomical region for each omics modality, it is likely that this introduced increased intra-assay variability due to over or under representation of different anatomical regions arising from difficulties in dissecting perfectly reproducible 1/6th portions form the kidney. And as the kidney is relatively heterogeneous organ, it is likely inter-assay comparisons may be confounded by differences in anatomical regions present in different 1/6th portions from the same kidney. All other missions' whole or hemi-sected or hemisected kidneys were processed

under dry-ice/liquid nitrogen to generate a homogenised powder to ensure all anatomical regions were proportionally represented and results from assays could be more accurately compared to one another.

<u>Ethics</u>

All human and animal experiments were approved by institutional animal care and use committees (IACUC/AREC) and human research ethics committees (HREC). In line with the principles of the 3Rs, extant data and tissues were used where possible to reduce the use of additional animals. Human data was anonymised, and group data averages were used where possible to maintain anonymity.

<u>Epigenome</u>

Whole-genome bisulfite sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 ¹	Silveira <i>et</i> <i>al., 2</i> 020 ²	Silveira <i>et al.,</i> 2020 ²
RR-3	Kidney	OSD-163 ³	OSD-163 ³	Silveira <i>et</i> <i>al., 2020</i> ²	Silveira <i>et al.,</i> 2020 ²

Transcriptome

Bulk RNA sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 ¹	OSD-102 ¹	OSD-102 ¹
RR-3	Kidney	OSD-163 ³	OSD-163 ³	OSD-163 ³	OSD-163 ³
RR-7	Kidney	OSD-253 4	OSD-253 4	OSD-253 4	OSD-253 ⁴
RR-10	Kidney	OSD-462 5	OSD-462 ⁵	OSD-462 5	OSD-462 ⁵
RR-23	Kidney	OSD-513 ⁶	OSD-513 ⁶	OSD-513 ⁶	OSD-513 ⁶

MHU-3	Kidney	Suzuki <i>et al.,</i> 2020 ^{7,} OSD-457 ⁸	OSD-457 ⁸	GSE152382 9	See below
MHU-1	Plasma	Shiba <i>et al., 2017</i> ^{10,} OSD-532 ¹¹	OSD-532 ¹¹	GSE213808	GSE213808 ¹² , See below
JAXA	Plasma	OSD-530 ^{13,} <i>Muratani et al.,</i> 2024 ¹⁴	Not available	OSD-530 ^{13,} <i>Muratani et</i> <i>al., 2024</i> ¹⁴	OSD-530 ^{13,} <i>Muratani et al.,</i> 2024 ¹⁴ , See below

Differential abundance analysis

MHU-3

Through the Jupyter platform, accessing the Science Managed Cloud Environment (SMCE) database, the default settings were used to generate differential expression analysis, normalization, and volcanoplot using the DESeq2 library (v 1.38.3) ¹⁵in R language (v 4.2). Gene annotation for the differential expression analysis was performed with the bioMart library (v 3.16)^{16,17} to access the Ensembl database, searching for mouse-specific genes (mmusculus gene ensembl).

MHU-1

Only ground control and microgravity groups were compared for the analysis.

JAXA

Reads in FASTQ files were imported into CLC Genomics Workbench (CLC-GW, ver.10.1.1, Qiagen), mapped to the human (hg19) reference genome, and quantified using a 57,773-gene (human) downloaded from the CLC-GW server to obtain the total count values, which were combined into a table. To plot normalized expression values, total counts were normalized by the scaling option in CLC-GW (normalization value = mean, reference = median mean, trimming 5%). Normalized total count values were log-2 transformed after adding a pseudocount of unity. ANOVAs and Empirical analyses of DGEs with pairwise EDGE test comparisons were performed

in CLC-GW to obtain the fold-change, weighted difference, nominal P-value and FDR-corrected P-value. For the analysis, samples from timepoints L-168d, L-112d and L-56d were pooled and averaged into "pre-flight" for pairwise comparison to either L+5d or L+120d.

Bulk small RNA sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
BNL-1	Plasma	<i>Malkani et al.,</i> 2020 ^{18,} OSD-336	OSD-336 ¹⁹	<i>Wuu et al.,</i> 2020 ²⁰	See below

miRNA WGCNA and target pathway analysis

The R package weighted correlation network analysis (WGCNA)²¹ was used to find clusters (ME; module-eigengenes) of highly correlated plasma miRNA transcripts with a high likelihood of coexpression and similar biological function. Dendrograms and heatmaps were generated for all MEs and aggregate differential abundances were calculated for each ME comparing Sham to GCR-exposed animals.

The miRNAs in these MEs were then input into MicroRNA ENrichment TURned NETwork (MIENTURNET²²) webtool to perform TargetScan-based miRNA-target Enrichment analysis using the default settings. This produced a list of mRNAs that were targeted by at least miRNAs within the MEs, and those with a nominal P-value <0.05 underwent DisGeNET²³ or KEGG ²⁴pathway using Metascape²⁵ with default settings. Mouse genes were imported as mouse and analysed as human. This was repeated for miR-125b and miR-16.

Spatial RNA sequencing

10um sections of fresh-frozen axial kidney sections from BNL-1 sham and GCR-exposed mice (n=3 per group) were processed according to the Slide-seqV2 protocol²⁶. Samples were sequenced on an Illumina NovaSeq S2 flow cell 200 cycle kit with a read structure of 43 bases for read 1, 8 bases for the i7 index read and 60 bases for read 2. Each puck received ~340 million reads, corresponding to ~3,400 to ~5,100 reads per bead. Transcripts were then mapped back to bead coordinates and cell type classifications were assigned to each bead (and colour-coded) with the robust cell type decomposition (RCTD) method²⁷ using a pre-existing mouse kidney cell atlas²⁸.

For differential abundance analysis of transcripts per cell type, all beads of a given class were summed from across n=3 pucks per groups, means were then log₂ transformed and DESeq2¹⁵ was used to calculate log-fold change, nominal p-values and adjusted p-values. Those with adjusted p-values <0.05 were listed in **Fig.9D**, and then for each cell type those transcripts with a nominal P-value <0.05 underwent DisGeNET²³ or KEGG²⁴ pathway using Metascape²⁵ with default settings. Mouse genes were imported as mouse and analysed as human.

qPCR

Pre-validated SYBR® green PrimePCR[™] primers (Bio-Rad) were used for qPCR analysis of reference genes (*B2m, Rps18, Tfrc, Tbp, Ube2d2*), mitochondrial fission markers (*Dnm11, Fis1, Mff*) and fusion markers (*Mfn1, Mfn2, Opa1*) in RNA extracted from RR-10 whole kidney homogenate⁵. Reference gene stability and normalisation factor calculations were done in RefFinder²⁹. Normalised relative abundances were then calculated for each of the fusion and fission markers for RR-10 ground control (n=7) vs spaceflight mice (n=8). To look for relative changes in all markers of fission and fusion, the geometric mean was calculated for both the fission and fusion markers, separately for each animal, and the arithmetic mean of these was then used to compare between groups in GraphPad Prism 9 (v.9.5.1).

The following primers were used:

Gene - assay ID:

- Dnm1I qMmuCID0021702
- Fis1 qMmuCID0020479
- Mff qMmuCID0017784
- Mfn1 qMmuCID0022027
- Mfn2 qMmuCID0023456
- Opa1 qMmuCID0010500
- B2m qMmuCID0040553
- Rps18 qRnoCID0057002
- Tbp qMmuCID0040542
- Tfrc qMmuCID0039655
- Ube2d2 qMmuCID0025334

Proteome

Quantitative fractionated TMT-labelled DDA LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Kidney	OSD-102 ¹	OSD-102 1	Silveira <i>et</i> <i>al., 2020</i> ²	Silveira <i>et al.,</i> 2020 ²
RR-3	Kidney	OSD-163 ³	OSD-163 ³	Silveira et al., 2020 ²	Silveira <i>et al.,</i> 2020 ²
RR-10	Kidney	OSD-462 5	OSD-462 5	OSD-462 ⁵	OSD-462 ⁵

Data acquisition and processing

Either fresh-frozen whole (BNL-3) or axially hemisected kidneys (NSRL-22A), were homogenised in 1 mL of 1 ml lysis buffer (8M urea, 2M thiourea, Complete protease inhibitor (#1186153001) Phostop protease inhibitor (PHOSS-RO, both Merck)) using the Precellys 24

Tissue homogeniser (6500 rpm, 1x 15 secs) with Lysing Matrix beads (#6913100, MPI Bio). After centrifugation at 15,000 rpm for 5 mins to pellet cellular debris, supernatant was removed and stored at -80°C. 0.5 mL of guanidine hydrochloride buffer (4M GuHCl, 50mM sodium acetate, 25 mM EDTA in ddH₂O, pH 5.8) was added to the pellet with a metal bead (#69989, 5mm, Qiagen) and vortexed at 1300 rpm for 1 hr at room temperature. Once the metal bead was removed, 1.5 ml of ice-cold ethanol was added to the supernatant, vortexed and incubated at -20°C overnight. Precipitates were pelleted at 15,000 rpm for 5 mins, and the ethanol was carefully removed, before drying in a SpeedVac. The original supernatant was then thawed and combined with the dried precipitated pellet material, vortexed well to solubilise and centrifuged again at 15,000 rpm for 5 mins. Protein concentration was quantified with a Bradford assay.

In-solution reduction, alkylation and digestion with trypsin was performed according to a routine digestion protocol prior to subsequent analysis by mass spectrometry. Cysteine residues were reduced with dithiothreitol and derivatised by treatment with iodoacetamide to form stable carbamidomethyl derivatives. Trypsin digestion was carried out overnight at room temperature after initial incubation at 37°C for 2 hours. The digested samples were cleaned up with PR-C18 resins. The cleaned peptide samples were resuspended in loading buffer for LC-MS/MS analysis.

For TMT labelling the cleaned peptide samples were resuspended in 100mM TEAB and labelled with *TMTpro* tags based on the user guide protocol. TMT tag labelling efficiency check showed >99%, and all 16plex tags were combined as one TMTpro set. Three TMTpro sets were generated, with a master pooled reference standard labelled with the 134N tag, allowing up to 45 experimental samples to be investigated that were randomised across the tags and sets (but allowing for equal proportions of each group per set).

In order to explore deeper into the proteome, a fractionation of TMTpro labelled peptide mix prior to LCMS analysis was performed using a high pH reversed phase HPLC. We used an Ultimate 3000 HPLC equipped with a degasser and a UV detector. Mobile phase A was 0.1%

triethylamine (aq), Mobile phase B was 0.1% triethylamine in acetonitrile. Peptides were subjected to a ZORBAX 300Extend-C18 column (4.6 mm inner diameter x 150 mm length, 3.5 µm particle size, part no. 763973-902, Agilent Technologies) and eluted out in a 20-min long two-step linear gradient from 0% to 50% for 9 min and from 50% to 90% buffer B for 1 min and keeping 90% buffer B for another 1 min, at a flow rate of 0.4 ml/min. The peptide mixture was fractionated into a total of 16 fractions, which were consolidated into 8 super-fractions. Peptide fractions were dried using a vacuum centrifuge and resuspended in 2% acetonitrile, 0.05% TFA (aq).

Chromatographic separation was performed using an Ultimate 3000 NanoLC system (ThermoFisherScientific, UK). Peptides were resolved by reversed phase chromatography on a 75µm*50cm C18 column using a three-step gradient of water in 0.1% formic acid (A) and 80% acetonitrile in 0.1% formic acid (B). The gradient was delivered to elute the peptides at a flow rate of 250 nl/min over 120 min. The eluate was ionised by electrospray ionisation using an Orbitrap Fusion Lumos (ThermoFisherScientific, UK) operating under Xcalibur v4.4. The instrument was programmed to acquire MS data using "Synchronous Precursor Selection with Multi-notch MS3" method (SPS MS3) by defining a 3s cycle time among a full MS scan, MS/MS fragmentation and MS3 fragmentation. We acquired one full-scan MS spectrum at a resolution of 120,000 at 200 m/z with 100% normalized AGC target and a scan range of 400~1500m/z and maximum injection time 100 ms. The MS/MS fragmentation was conducted using collision-induced dissociation (CID) and quadrupole ion trap analyzer. Parameters were set up as 100% normalized AGC target, NCE (normalized collision energy) 35, q-value 0.25, isolation window 1.2 Th and maximum injection time 50 ms. The MS3 scan was analyzed using higher-energy collision dissociation (HCD) and Orbitrap analyzer with a synchronous precursor selection. Parameters included number of SPS 10, NCE 65, 400% normalized AGC target, maximum injection time 105 ms, resolution 50,000 at 200 Th, isolation window 1.6. 2-6 charged states were defined within this method.

Raw mass spectrometry data were processed into peak list files using Proteome Discoverer (ThermoScientific; v2.5) (PD 2.4). Processed data was then searched using Sequest search

engine embedded in PD 2.5, against the current version of the reviewed Swissprot *Mouse* database downloaded from Uniprot³⁰. The following parameters were used:

Spectrum Selector

Min. Precursor mass:	350 Da
Max. Precursor mass:	10000 Da
S/N Threshold (FT-only):1.5	

Mascot/Sequest

Database:	Uniprot
Enzyme:	Trypsin
Missed cleavage:	2
Precursor mass tol:	10 ppm
Fragment mass tol:	0.6 Da
Dynamic modifications:	

Carbamidomethyl (C)
Oxidation (M)

Peptide validator

Target FDR (strict):	0.01
Target FDR (relaxed):	0.05

TMT Reporter Quantification

Co-Isolation Threshold.: 50

SPS Mass Matches[%] Threshold: 50 (65 as default) Average Reporter S/N Threshold: 10

Quantitative label-free SEER DIA LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Inspiration4	Plasma	OSD-571 ³¹	By Request	OSD-571 31	OSD-571 ³¹ , See
-					"DAA" below
Inspiration4	Exosome	OSD-571 32	By Request	OSD-571 32	OSD-571 ³² , See
					"DAA" below

Plasma Slow Off-Rate Modified Aptamers

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-19	Plasma	<i>Lee et al., 2020</i> ^{33,} OSD-342 ³⁴	OSD-342 ³⁴	OSD-342 ³⁴	See "DAA"

Shotgun LC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Cosmonauts	Urine	Pastushkova et al., 2013 ³⁵	PASS00239 36	PASS00239 36	See below

Network Analysis

Cosmonaut (n=10 per timepoint) urinary shotgun proteomes pre-flight were compared with those measured post-flight R+1d and R+7d. Proteins that were absent pre-flight but detected after spaceflight were taken forward for network analysis in Cytoscape StringApp³⁷ using the latest version of the STRING³⁸ database. This was then visualised in Cytoscape using the yFiles Tree layout, excluding singletons.

Differential abundance analysis (DAA)

In-house R scripts were used for proteomics data processing and statistical analysis. The corrected reporter intensity values were used to analyse proteomics data. Protein groups containing matches to decoy database or contaminants were discarded. Total intensity for each reporter were calculated and matched to correct for the sample loads in each experiment. Only proteins that were quantified in the pooled samples were used for the analysis. Subsequently, internal reference scaling (IRS) method was employed to normalize protein intensities between different runs using common proteins in pooled internal standards. The data was log2 transformed and scaled by subtracting the median for each sample. LIMMA was employed to determine differentially abundant proteins between groups.

Inspiration4

For the analysis, samples from timepoints L-92d, L-44d and L-3d were pooled and averaged into "pre-flight" for comparison to immediate post-flight R+1d.

Epiproteome

Quantitative fractionated TMT-labelled DDA LC-MS/MS of phospho-enriched peptides

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-10	Kidney	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵	OSD-462 ⁵, See below

Differential abundance analysis

In-house R scripts were used for phosphoproteomics data processing and statistical analysis. Only phosphopeptides with a single modified residue were considered for further analysis. These phosphopeptides were mapped back to genes with the residue amino acid and position annotated. The data was log2 transformed and LIMMA was employed to determine differentially abundant phosphopeptides between groups. For analyses that required single entries for each gene, the phosphopeptides were collapsed into a single gene and their intensity scores aggregated to obtain a generalised change in the overall phospho-status of the protein encoded by that gene.

<u>Metabolome</u>

Quantitative label-free UHPLC-MS/MS

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
Inspiration4	Plasma	OSD-571 ³⁹	By Request	OSD-571 ³⁹	OSD-571 ³⁹ , See below
MHU-3	Plasma	Suzuki et al., 2020 ^{7,} Uruno et al., 2021 ⁴⁰	By Request	ibSLS ⁴¹	See below
CNSA	Serum	Zhang et al., 2020	By Request	Zhang et al., 2020 ⁴²	<i>Zhang et al.,</i> 2020 ⁴² , See below

Differential abundance analysis

Inspiration4

For the analysis, samples from timepoints L-92d, L-44d and L-3d were pooled and averaged into "pre-flight" for comparison to immediate post-flight R+1d.

MHU-3

For the analysis, samples from ground control and spaceflight animals were directly compared for timepoints L+18d and R+2d. Data were Log₂ transformed, fold changes were calculated, and nominal p-values and adjusted p-values were determined in GraphPad Prism 8 using the multiple tests option.

Over-representation analysis

Metabolites with a nominal P-value of <0.05 and which had a successful name check were taken forward for KEGG module pathway analysis (targeted) using MetaboAnalyst 5.0⁴³ with the default settings.

Microbiome

Whole metagenome shotgun sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-6	Faeces	OSD-249 44	OSD-249 44	See "DP"	See "DAA"
RR-9	Faeces	OSD-250 45	OSD-250 45	See "DP"	See "DAA"
RR-10	Faeces	OSD-466 46	OSD-465 46	See "DP"	See "DAA"
RR-23	Faeces	OSD-465 47	OSD-465 47	See "DP"	See "DAA"

16S rRNA gene amplicon sequencing

Cohort	Specimen	Experiment	Raw Data	Processed	Analysis
RR-1	Faeces	<i>Jiang et al.,</i> 2019	OSD-212 49	<i>Jiang et al.,</i> 2019 ⁴⁸	<i>Jiang et al., 2019</i>
STS-135	Faeces	<i>Ritchie et al.,</i> 2015 ⁵⁰	OSD-72 51	Ritchie et al., 2015 ⁵⁰	Ritchie et al., 2015 ⁵⁰

Data processing (DP) and differential abundance analysis (DAA)

Sequence data were processed using the Nephele platform⁵², provided by the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, MD (1). The Whole metaGenome Sequence Assembly pipeline, version 2 (WGSA2), was employed to assess whole-genome shotgun sequencing data. Additionally, pre-processed amplicon sequencing taxa abundance data from RR-1 and STS-135 were obtained from previous publications.

Data analysis was conducted using R (Version 4.2.1). Centred log-ratio transformed abundance values of the observed taxa detected in over 10% of the samples were calculated. Differential abundance between mission-matched Flight and Ground Control groups was evaluated using a linear model, followed by a Benjamini-Hochberg False Discovery Rate correction. Relevant R libraries utilised in this analysis can be found online^{53,54}.

For a comprehensive multi-omics analysis, total microbiome differential abundance results were employed. A kidney stone (KS) relevant microbe list was compiled from existing literature, which was then used for targeted differential abundance assessment. Directionality, degree, and significance of difference measures between groups for each mission were compiled for comparative purposes.

Physiology

Sample collection and processing

NSRL-22A

Urine collection was performed in awake mice to obtain spontaneous and uncontaminated samples. Mice were gently handled over a sheet of Saran® wrap or Parafilm® to facilitate micturition. Upon collection, each urine sample was carefully divided into two aliquots. One aliquot was immediately acidified with HNO3 to achieve a final concentration of 1% v/v, preventing precipitation of electrolytes and maintaining sample integrity. Both aliquots were then promptly stored at -80°C to preserve their biochemical constituents until further analysis. For blood collection, mice were subjected to terminal anaesthesia to minimize distress and ensure compliance with ethical guidelines. Blood samples were drawn from the vena cava using a fine needle and syringe. Plasma was separated by transferring the blood into Microvette® CB 300 LH (Sarstedt) tubes and centrifuging at 2000 g for 5 min. The resulting plasma supernatant was carefully aspirated and stored at -80°C for future analysis. Both plasma and non-acidified urine samples were analysed for creatinine levels by employing either the standard Jaffe reaction or the enzymatic method, depending on the investigator's preference and laboratory resources. Electrolyte levels, biochemistries and biomarkers were assessed using the Siemens Dimension RxL Max Integrated Chemistry System, at the Core Biochemical Assay Laboratory at Addenbrooke's Hospital, Cambridge, UK.

Inspiration4

Plasma samples collected from astronauts at timepoints L-92d, L-44d and L-3d were grouped and averaged into "pre-flight" for comparison against individual post-flight timepoints R+1d, R+45d, R+82d and R+194d. These samples were analysed by Quest Diagnostics using the Comprehensive metabolic panel [CMP; CPT code 80053].

NASA

A historical collection of archived astronaut frozen plasma and urine aliquots were collected and stored at -80C over many years. Clinical chemistries, endocrine profiles and biomarkers were obtained at the Nutritional Biochemistry Laboratory at NASA Johnson Space Center. Timepoints L-180d and L-45d were grouped and averaged as "pre-flight" for comparison to individual timepoints L+15d, L+30d, L+60d, L+120d, L+180d, R+0d and R+30d.

Functional calculations

eGFR was calculated using the new 2021 CKD-EPI creatinine (2009 CKD-EPI creatinine fit without race) [new eGFRcr(AS) equation⁵⁵]. The fractional excretions of electrolytes were determined by (Urine solute x Plasma creatinine) \div (Urine creatinine x Plasma solute). A corrected FE_{Mg} was determined, as ~30% of magnesium is protein bound and is not filtered, and therefore the plasma magnesium must be multiplied by 0.7 i.e. [pCr × uMg] / [(0.7 × sMg) × pCr]⁵⁶. The FE_{H20} is the volume of water that appears as urine compared to the amount filtered. Thus, FE_{H20} = V / GFR. Since GFR = UCr x V / PCr. FE_{H20} = V x PCr / UCr x V. Simplifying, FE_{H20} = PCr / UCr (then multiply by 100 to express as a percentage⁵⁷). The ratio of tubular maximum reabsorption of phosphate (TmP) to GFR is used to evaluate renal phosphate transport. TmP/GFR is calculated using the following steps: 1) Calculate the ratio of phosphate clearance to creatinine clearance (CP/CCr) CP/CCr = serum creatinine x Urine phosphate / Urine creatinine x Serum phosphate (This ratio is normally less than 0.15 and is often elevated in primary hyperparathyroidism). 2) Subtract this fraction from 1.0 to give the fractional tubular reabsorption

of phosphate (TRP). TRP = 1 - serum creatinine x Urine phosphate / Urine creatinine x Serum phosphate. 3) If TRP is \leq 0.86 then phosphate reabsorption is maximal and there is a linear relationship between plasma phosphate concentration and excretion and TmP/GFR which is calculated by: TmP/GFR = TRP x serum phosphate. 4) If TRP is > 0.86 relationship between plasma phosphate concentration is curvilinear and TmP/GFR is defined as follows: TmP/GFR = α x serum phosphate, where α = 0.3 x TRP 1- (0.8 x TRP)⁵⁸. The transtubular potassium gradient (TTKG) is used to gauge renal potassium secretion by the cortical collecting duct, indirectly assessing mineralocorticoid bioactivity in patients. TTKG = U_K/P_K x P_{Osm}/U_{Osm}⁵⁹. Estimated serum osmolality was determined using the Khajuria and Krahn equation: OSMc = 1.86(Na + K) + 1.15(Glu / 18) + (Urea / 6) + 14⁶⁰. Free water clearance is calculated as C_{H2O} = V(1-U_{Osm}/P_{Osm}⁶¹).

Multi-omic integrated pathway over-representation analyses

To integrate datasets from across different omics, species, missions and tissues, all biomolecules (e.g. phosphoproteins, proteins, transcripts and methylated DNA) were linked back to their HGNC gene symbol, aggregated and collapsed to single genes (e.g. multiple phosphosites, isoforms, CpG sites) and converted to the human orthologs where necessary. To perform over-representation analysis in Metascape²⁵ using any of the pathway databases, the less stringent nominal p-value of P<0.05 was used to threshold differentially expressed hits within each dataset for analysis (with the exception of RR-23 where the adjusted p-value was used to threshold the number of hits to a manageable number), with a -Log₁₀(P-value) of 2 being considered significant for ontological term enrichment. This approach reduces the risk of false-negatives due to potentially overly stringent multiple comparison adjustment of the p-value at an individual dataset level, while mitigating the risk of false-positives at the convergence of hits during ontological term enrichment. The degree of confidence in the validity of results can then be drawn from the robustness of replication across orthogonal and/or independent datasets.

DisGeNET²³ analysis was performed using Metascape with default settings. Differentially expressed gene lists (p.value <0.05) from each dataset were imported into Metascape. Mouse genes were imported as mouse and analyzed as human. DisGeNET outputs containing enriched human disease terms (-LogP >2) were downloaded and visualized using Python's seaborn and matplotlib libraries. The circle size represents –LogP values and the circle color represents enrichment ratio.

KEGG pathway analysis²⁴ was performed using Metascape with default settings. Differentially expressed gene lists (p. value < 0.05) from each dataset were imported into Metascape. Mouse genes were imported as mouse and analyzed as human. KEGG outputs containing enriched KEGG pathways (-LogP >2) were downloaded and visualized using Python's seaborn and matplotlib libraries. The circle size represents –LogP values and the circle colour represents enrichment ratio.

Enriched GO⁶² terms were obtained from clusterProfiler outputs. GO enrichments containing biological process ontologies were visualized using Python's seaborn and matplotlib libraries. The circle size represents –LogP values and the circle color represents enrichement ratio.

For analysis of significant genes (p. value < 0.05) that had a consensus in directionality, we only used kidney proteomic and transcriptomic datasets and ranked according to the \log_2 fold change direction and the number of times observed across all datasets. The highest ranked upregulated and downregulated genes were plotted using CoMut⁶³.

Integration of multi-omics and physiological data

The Scalable Precision Medicine Open Knowledge Engine (SPOKE)⁶⁴ is a population-level heterogeneous knowledge graph. SPOKE has distilled and connected information from over 40 databases into a structured graph with 21 different node types and 55 edge types. The databases

cover numerous biomedical domains, from basic science to clinical research. Previously, SPOKE was leveraged to analyse GeneLab gene expression data from mice flown in space. Using only data from mice, this study uncovered biological and clinical changes experienced by human astronauts.

Due to the heterogeneous structure of SPOKE, it is possible to harmonise multi-omics datasets. This is achieved by identifying "entry points" for each dataset. Entry points represent the logical overlap between SPOKE nodes and the entity being quantified in the dataset. Here entry points consisted of Gene (transcriptome and epigenome), Protein (proteome and post-translation modification), and Compound (metabolome) nodes. Once the external datasets were connected to SPOKE, Degree Weighted Path Count (DWPC) was used to score the connectivity between each entry node and the nodes in SPOKE. The top 5% of nodes from each entry point were merged into a single graph. The interconnected paths between the entry points provide a system-level view of how space flight impacts the kidneys. The resulting knowledge map figures highlight shared paths that traverse nodes involved in kidney morphogenesis, kidney stones, and chronic kidney disease.

<u>Imaging</u>

Sample fixation and processing

Mouse kidney samples were harvested and fixed through immersion in freshly prepared 4% (w/v) formaldehyde-PBS solution (pH 6.9) for 16 hours at 37°C. Subsequently, the samples were washed three times with PBS with 0.02% Na-Azide and stored at 4°C until they were embedded in paraffin.

Histopathology and Brightfield WSI

2-3 µm FFPE sections from NSRL-22A kidneys were prepared, deparaffinised using Histoclear (National Diagnostics), and rehydrated through a series of graded methanol steps. These were then stained for either Haematoxylin & Eosin (#ab245880, Abcam) or Masson's Trichrome (#ab150686, Abcam) according to the manufacturers guidelines.

Sections underwent brightfield whole slide imaging with 20X objective tiled and stitched focus stacks taken for each section on a Zeiss Axio Scan.Z1 slide scanner. The resultant images were viewed in QuPath (v0.4.3) and semi-quantitatively scored for any histopathological findings.

Immunostaining and Confocal WSI

5 µm FFPE sections from RR-10 kidneys were prepared, deparaffinised using Histoclear (National Diagnostics), and rehydrated through a series of graded methanol steps. Antigen retrieval was performed using [1X] R-Universal buffer (AP0530) in a 2100 antigen retriever for a single heat-pressure cycle (Aptum Biologics). Sections were then permeabilized with 0.05% (v/v) Triton X-100-PBS solution for 20 minutes and incubated with Section Block 'ready-to-use' (AP0471; Aptum Biologics) for 30 mins at RT. Primary antibodies were incubated overnight at 4°C for 16 hours at specified concentrations below, diluted in Antibody Diluent 'FF/PE Sections' (AP0472; Aptum Biologics). For phospho-specific antibodies, 10 µg/ml of the non-phospho peptide used to raise the antibody was added per 2 µg/ml of the antibody used. Negative control samples omitted the primary antibody and were processed simultaneously. Following incubation, slides were washed by dipping slides 50x times in 0.05% (v/v) Triton X-100-PBS for 3 rounds, and incubated with secondary antibodies for 1 hour at RT. Pre-absorbed fluorochrome conjugated secondary antibodies were utilised at the concentrations below, diluted in Antibody Diluent 'FF/PE Sections' (AP0472; Aptum Biologics). After washing, slides were mounted using Prolong Gold antifade (#P36930, Life Technologies), permitted to cure for 48-72hrs, sealed with CoverGrip Coverslip Sealant (#23005; Biotium) and protected from light exposure.

Immunofluorescent images were captured using either a Zeiss LSM700 LED laser-scanning confocal microscope or Leica SP8 white-light laser-scanning confocal microscope using 488-nm, 555-nm and 639-nm laser lines, employing a 10X/0.3NA (Zeiss) or 10X/0.5NA (Leica) objective. Zeiss acquisition parameters included single field of view, 8-bit resolution, 1844 x 1844 pixels, 1x digital zoom, 3.85µs pixel dwell time, 4-line Kalman filtering, sequential (by line) channel imaging, and a 4-slice z-stack with a 6 µm thickness to account for chromatic aberration.

Leica acquisition parameters included tile scanning with a 10% overlap, 8-bit resolution, 1024 × 1024 pixels, 0.75x digital zoom, 600 Hz scan speed, 6-line Kalman filtering, sequential (by line) channel imaging, and a 3-slice z-stack with a 5 µm thickness to account for chromatic aberration.

Images were processed using FIJI image analysis software (v.1.53p). Fluorescent z-stacks underwent background subtraction (200 px radius rolling ball) and maximum intensity z-projection. Brightness and contrast adjustments were made using linear histogram stretching to enhance visibility.

PRIMARIES

Target: anti-rat total NCC (tNCC) [cross reacts with mouse and human total NCC]

Host species: Rabbit

Clonality: pAb full IgG

Product: Abcam (ab95302)

Lot #: GR3274565-9

Working Concentration: @2ug/mL

Validation: Previously published in two models that increase or decrease NCC expression (https://doi.org/10.1093/hmg/ddv185 and https://doi.org/10.15252/emmm.201505444)

Target: anti-human phospho-NCC (pNCC) Thr46, Thr50, Thr55 [cross reacts with mouse pNCC Thr44, Thr48, Thr53]

Host species: Sheep

Clonality: pAb full IgG

Product: MRC PPU Reagents and Services (S908B)

Lot #: 2nd Bleed

Working Concentration: @2ug/mL (+ 10ug/mL non-phosphopeptide to ensure specificity)

Validation: Previously published in model that decreases NCC phosphorylation (https://doi.org/10.1093/hmg/ddv185)

Target: anti-human phospho-NCC (pNCC) Thr60 [cross reacts with mouse pNCC Thr58]

Host species: Sheep

Clonality: pAb full IgG

Product: MRC PPU Reagents and Services (S995B)

Lot #: 1st Bleed

Working Concentration: @2ug/mL (+ 10ug/mL non-phosphopeptide to ensure specificity)

Validation: Previously published in model that increase or decreases NCC phosphorylation (https://doi.org/10.1093/hmg/ddv185 and https://doi.org/10.15252/emmm.201505444)

SECONDARIES

Target: Alexa Fluor 647 anti-goat IgG (cross reacts with sheep IgG)

Host species: Donkey

Clonality: pAb IgG Fab Fragment

Product: Jackson ImmunoResearch (711-607-003)

Working Concentration: @8ug/mL

Validation: (lots of citations) https://www.jacksonimmuno.com/catalog/products/711-607-003

Target: Alexa Fluor 647+ anti-Goat IgG (cross reacts with sheep IgG)

Host species: Donkey

Clonality: pAb full IgG

Product: ThermoFisher (A32849)

Working Concentration: @10ug/mL

Validation: (lots of citations) https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32849

Target: Alexa Fluor 555+ anti-rabbit IgG

Host species: Donkey

Clonality: pAb full IgG

Product: ThermoFisher (A32794)

Working Concentration: @10ug/mL

Validation: (lots of citations) https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32794

Target: Alexa Fluor 488 anti-rabbit IgG

Host species: Donkey

Clonality: pAb IgG Fab Fragment

Product: Jackson ImmunoResearch (711-547-003)

Working Concentration: @8ug/mL

Validation: (lots of citations) https://www.jacksonimmuno.com/catalog/products/711-547-003

miRNA in situ hybridisation and brightfield WSI

FFPE blocks for BNL-3 kidneys were trimmed to remove tissue exposed to air, and fresh 5µm sections were taken. These were not baked onto the slide and stored with desiccant instead. Samples were then processed using the miRNAscope™ HD RED assay (#324531 and #324500,

ACD-Biotechne) with the FFPE tissue section workflow according to the manufacturers guidelines. miRNAscope[™] Probes against the following were used: mmu-miR-125b-5p (#1082311-S1), mmu-let-7a-5p (#727761-S1) and mmu-miR-16-5p (729031-S1).

Sections underwent brightfield whole slide imaging with 20X objective tiled and stitched focus stacks (with extended depth of focus) taken for each section on a Zeiss Axio Scan.Z1 slide scanner. Using QuPath (v0.4.3) the cortex, outer stripe of the outer medulla, inner stripe of the outer medulla and inner medulla were manually annotated with the aid of a Wacom cintiq pro 32 to create a segmentation mask of the anatomical regions for area calculation. Ilastik (v1.4.0)⁶⁵ automated (supervised) pixel-level classification was then trained to identify positive miRNAscope probe staining. A custom in-house python script was then used to count all positive staining and calculate the area of all anatomical regions, so that the density of each miRNA per unit area of each region could be determined for each kidney section.

Optical Clearing and 3D imaging

Tissue transformation, delipidation and refractive index matching

Quartered formaldehyde-fixed kidneys from RR-10 mice were tissue transformed using the SHIELD protocol⁶⁶ and reagents from Lifecanvas technologies (MA, USA) based on (10.1038/nbt.4281). SHIELD-transformed kidneys were delipidated (Lifecanvas Technologies; Full Passive Pipeline Protocol v4.06) for approximately 10–14 days at 37°C in 40 mL of passive delipidation buffer with gentle agitation in EasyClear device. Following delipidation, tissues were washed in several rounds of PBS at 37°C overnight to remove any delipidation buffer. Before imaging tissues were immersed in Incubated in EasyIndex RI 1.53 refractive index matching solution as per protocol. Tissues were then embedded in 2% w/v ultra-low melting point agarose (Sigma A5030) blocks made up with EasyIndex solution to immobilise the samples. These were then stored in EasyIndex in airtight containers shielded from light prior to imaging.

MesoSPIM imaging

Samples were mounted in quartz cuvettes and immersion oil with refractive indices matching that of EasyIndex, and then suspended and aligned for light-sheet fluorescence imaging with a MesoSPIM⁶⁷. Images were captured at 16-bit for 1-channel dual laser lightsheet illumination (488 nm excitations) to obtain autofluorescence emissions at 2048 x 2048 pixels in the XY, with a Z depth range of 700-1200 pixels, giving a pixel resolution of 3.26 μ m (XY) and 4.0 μ m (Z).

Image analysis

To evaluate any qualitative changes in gross morphology images were imported into Syglass ⁶⁸ (v.1.7.2-79; https://www.syglass.io/; RRID: SCR_017961) for visual investigation by nephrologists and histopathologists in 3D virtual space using Meta Quest 2 VR headsets. Images were also imported into Imaris ⁶⁹(v10.0) for visualisation on a Wacom cintiq pro 32" 4K touchscreen monitor. <u>3D video renders</u> were later generated with Syglass (v.2.0.0) and Z-slice video created with FIJI (ImageJ; v.1.54h).

<u>Morphometry</u>

Normalised kidney weights

PI and NASA GeneLab records for all animals included in the study were examined for bodyweight and kidney wet weight measurements. Only BNL-1, BNL-2, BNL-3 and RR-23 missions had complete kidney and body weight information available. Where available, the weights of both left and right kidneys were averaged, and the kidney weights were normalised against bodyweight for the same animal and expressed as a percentage. All ground control and sham animals that received no exposure treatment were grouped into control for pairwise comparisons against GCR (animals that only received either full or simplified galactic cosmic radiation simulations) or MG (animals that only underwent hindlimb unloading microgravity simulation) or GCR + MG (animals that underwent a combination of GCR and MG or were exposed to spaceflight).

Histomorphometry

Whole slide images of tiled immunofluorescent confocal images taken from RR-10 were used for analysis. Using QuPath (v0.4.3) the cortex was manually annotated with the aid of a Wacom cintiq pro 32 to create a segmentation mask of the major anatomical regions for area calculation (e.g. cortex vs medulla). Similarly distal convoluted tubules (DCT) labelled with antibodies against total NCC / phospho-NCC, the canonical DCT marker, were annotated. Initially, only a handful of tubules were annotated from each slide, and these were then used to train Ilastik (v1.4.0)⁶⁵ for automated (supervised) pixel-level classification of DCTs. These were then further manually refined to remove/include any false-positive/negatives. A custom in-house python script was then used to compute the number of discrete tubules positive for DCT markers, the corresponding area of each of these as well as the total cortex area, such that average tubule area and DCT density per area of cortex could be determined for each kidney section.

REFERENCES

 NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-102.

- Silveira, W. A. da *et al.* Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact. *Cell* **183**, 1185-1201.e20 (2020).
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-163.
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-253.
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-462.
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-513.
- Suzuki, T. *et al.* Nrf2 contributes to the weight gain of mice during space travel. *Commun. Biol.* 3, 1–14 (2020).
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-457.
- 9. GEO Accession viewer.

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152382.

- Shiba, D. *et al.* Development of new experimental platform 'MARS'—Multiple Artificialgravity Research System—to elucidate the impacts of micro/partial gravity on mice. *Sci. Rep.* 7, 10837 (2017).
- 11. NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-532.
- Masafumi, M. GEO Accession viewer. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213808.
- NASA OSDR: Open Science for Life in Space.
 https://osdr.nasa.gov/bio/repo/data/studies/OSD-530.
- 14. Masafumi, M. CD36-associated extracellular mitochondria as a hallmark of space response.

- 15. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* 4, 1184– 1191 (2009).
- 17. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
- Malkani, S. *et al.* Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. *Cell Rep.* 33, 108448 (2020).
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-336.
- Wuu, Y.-R. *et al.* LET-Dependent Low Dose and Synergistic Inhibition of Human Angiogenesis by Charged Particles: Validation of miRNAs that Drive Inhibition. *iScience* 23, (2020).
- 21. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* **9**, 559 (2008).
- Licursi, V., Conte, F., Fiscon, G. & Paci, P. MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis. *BMC Bioinformatics* 20, 545 (2019).
- Piñero, J. *et al.* The DisGeNET knowledge platform for disease genomics: 2019 update.
 Nucleic Acids Res. 48, D845–D855 (2020).
- Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* 28, 27–30 (2000).
- Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
- 26. Stickels, R. R. *et al.* Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. *Nat. Biotechnol.* **39**, 313–319 (2021).

- Cable, D. M. *et al.* Robust decomposition of cell type mixtures in spatial transcriptomics.
 Nat. Biotechnol. 40, 517–526 (2022).
- 28. Miao, Z. *et al.* Single cell regulatory landscape of the mouse kidney highlights cellular differentiation programs and disease targets. *Nat. Commun.* **12**, 2277 (2021).
- 29. Xie, F., Wang, J. & Zhang, B. RefFinder: a web-based tool for comprehensively analyzing and identifying reference genes. *Funct. Integr. Genomics* **23**, 125 (2023).
- The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51, D523–D531 (2023).
- 31. Mason, C. E. Inspiration4 plasma proteomics. (2023).
- 32. Mason, C. E. Inspiration4 exosome proteomics. (2023).
- Lee, S.-J. *et al.* Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. *Proc. Natl. Acad. Sci.* **117**, 23942–23951 (2020).
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-342.
- Pastushkova, L. Kh. *et al.* Changes of Protein Profile of Human Urine after Long-Term Orbital Flights. *Bull. Exp. Biol. Med.* **156**, 201–204 (2013).
- 36. View a PASSEL Dataset.https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/PASS_View?identifier=PASS00239.
- Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *J. Proteome Res.* 18, 623–632 (2019).
- Szklarczyk, D. *et al.* The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**, D638–D646 (2023).
- 39. Mason, C. E. 39. Inspiration4 plasma metabolomics. (2023).
- Uruno, A. *et al.* Nrf2 plays a critical role in the metabolic response during and after spaceflight. *Commun. Biol.* 4, 1–18 (2021).

- 41. ibSLS Metabolite List -. https://ibsls.megabank.tohoku.ac.jp/metabolite-list.
- Zhang, H. *et al.* Serum Metabolomics Associating With Circulating MicroRNA Profiles Reveal the Role of miR-383-5p in Rat Hippocampus Under Simulated Microgravity. *Front. Physiol.* **11**, (2020).
- Pang, Z. *et al.* MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. *Nucleic Acids Res.* 49, W388–W396 (2021).
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-249.
- 45. NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-250.
- ASA OSDR: Open Science for Life in Space.
 https://osdr.nasa.gov/bio/repo/data/studies/OSD-466.
- NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-465.
- 48. Jiang, P., Green, S. J., Chlipala, G. E., Turek, F. W. & Vitaterna, M. H. Reproducible changes in the gut microbiome suggest a shift in microbial and host metabolism during spaceflight. *Microbiome* 7, 113 (2019).
- ASA OSDR: Open Science for Life in Space.
 https://osdr.nasa.gov/bio/repo/data/studies/OSD-212.
- 50. Ritchie, L. E. *et al.* Space Environmental Factor Impacts upon Murine Colon Microbiota and Mucosal Homeostasis. *PLOS ONE* **10**, e0125792 (2015).
- 51. NASA OSDR: Open Science for Life in Space. https://osdr.nasa.gov/bio/repo/data/studies/OSD-72.
- 52. Weber, N. *et al.* Nephele: a cloud platform for simplified, standardized and reproducible microbiome data analysis. *Bioinformatics* **34**, 1411–1413 (2018).
- 53. thomazbastiaanssen. 0. Introduction. (2023).

- 54. Bastiaanssen, T. F. S., Quinn, T. P. & Loughman, A. Bugs as Features (Part I): Concepts and Foundations for the Compositional Data Analysis of the Microbiome-Gut-Brain Axis. (2022) doi:10.48550/arXiv.2207.12475.
- Inker, L. A. *et al.* New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *N. Engl. J. Med.* 385, 1737–1749 (2021).
- Topf, J. M. & Murray, P. T. Hypomagnesemia and Hypermagnesemia. *Rev. Endocr. Metab. Disord.* 4, 195–206 (2003).
- 57. Coulthard, M. G. & Haycock, G. B. Distinguishing between salt poisoning and hypernatraemic dehydration in children. *BMJ* **326**, 157–160 (2003).
- Stark, H., Eisenstein, B., Tieder, M., Rachmel, A. & Alpert, G. Direct Measurement of TP/GFR: A Simple and Reliable Parameter of Renal Phosphate Handling. *Nephron* 44, 125–128 (2008).
- 59. Choi, M. J. & Ziyadeh, F. N. The Utility of the Transtubular Potassium Gradient in the Evaluation of Hyperkalemia. *J. Am. Soc. Nephrol.* **19**, 424–426 (2008).
- 60. Martín-Calderón, J. L. *et al.* Choice of the best equation for plasma osmolality calculation: Comparison of fourteen formulae. *Clin. Biochem.* **48**, 529–533 (2015).
- 61. Free water clearance. Wikipedia (2021).
- The Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine.
 Nucleic Acids Res. 49, D325–D334 (2021).
- 63. Crowdis, J., He, M. X., Reardon, B. & Van Allen, E. M. CoMut: visualizing integrated molecular information with comutation plots. *Bioinformatics* **36**, 4348–4349 (2020).
- 64. Morris, J. H. *et al.* The scalable precision medicine open knowledge engine (SPOKE): a massive knowledge graph of biomedical information. *Bioinformatics* **39**, btad080 (2023).
- Berg, S. *et al.* ilastik: interactive machine learning for (bio)image analysis. *Nat. Methods* 16, 1226–1232 (2019).
- Park, Y.-G. *et al.* Protection of tissue physicochemical properties using polyfunctional crosslinkers. *Nat. Biotechnol.* **37**, 73–83 (2019).

- 67. Voigt, F. F. *et al.* The mesoSPIM initiative: open-source light-sheet microscopes for imaging cleared tissue. *Nat. Methods* **16**, 1105–1108 (2019).
- Pidhorskyi, S., Morehead, M., Jones, Q., Spirou, G. & Doretto, G. syGlass: Interactive Exploration of Multidimensional Images Using Virtual Reality Head-mounted Displays. Preprint at https://doi.org/10.48550/arXiv.1804.08197 (2018).
- 69. Imaris Microscopy Image Analysis Software | Comparison Imaris. *Oxford Instruments* https://imaris.oxinst.com/packages.